Scott Edmondson leaves AstraZeneca, starts new chapter at Nimbus; With IPO filed, Taysha pulls together an AveXis-heavy team
→ Nimbus Therapeutics, which identified 4 new targets – AMPKβ2, CTPS1, Cbl-b and WRN – in their drug discovery efforts,
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
